What cannabis sales data can and cannot tell us about young adult risk: a critical commentary on retail trends and clinical practice

BACKGROUND: Cannabis retail sales data from legalized markets provide a valuable but incomplete view of young adult consumption patterns. Recent analyses of California's commercial cannabis transactions show that, although flower accounts for the largest share of spending, young adults allocate a greater proportion of cannabis expenditure to vapor pens and concentrates than older adults. These trends raise important clinical and public health concerns. METHODS: This commentary critically evaluates the strengths and limitations of retail analytics using established appraisal frameworks and considers the implications for clinical assessment, harm reduction, and policy development. RESULTS: Retail datasets have inherent limitations that restrict their usefulness as indicators of individual risk. Transaction logs cannot capture frequency of use, dosage, motivations, psychosocial influences, or associated harms, and they exclude illicit market activity, which represents a substantial proportion of young adult consumption. CONCLUSIONS: Retail data should be interpreted as macro-level indicators rather than direct proxies for personal use. Effective risk assessment requires integrating commercial analytics with qualitative insight, epidemiological surveillance, and updated clinical screening approaches that reflect modern high-potency cannabis modalities. The commentary also considers how these findings translate to international contexts, including the United Kingdom, where unregulated markets and product mislabeling present additional challenges for frontline practitioners.